Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia

Westwood, Jennifer; Geraghty, Robert; Jones, Patrick; Prasad, Bhavan; Somani, Bhaskar K.

doi:10.1177/1756287218793084

Cited by 70 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for this difference in discriminatory power remains speculative and could be due to patient selection, case mix, indication for surgery, or sample size, but also differences in the geriatric assessment. The lower success rate of TURP in frail patients paralleled by higher anaesthesiologic and complication risks in most series underline the role of less invasive procedures such as Rezum, UroLift, or prostate embolization in this cohort [12][13][14]. Although none of the studies with these procedures have applied a systematic geriatric assessment, the failure rates reported in patients "unfit for surgery" are not dissimilar to those after TURP in frail patients.…”

Section: Discussionmentioning

confidence: 91%

Can a Simple Geriatric Assessment Predict the Outcome of TURP?

et al. 2020

View full text Add to dashboard Cite

KeywordsTURP · Geriatric · Outcome · Geriatric assessment · Benign prostatic hyperplasia · Lower urinary tract symptoms Abstract Purpose: To determine the impact of a simple preoperative geriatric assessment on the outcome in older patients with recurrent urinary retention who underwent desobstructive surgery. Patients and Methods: Patients aged 75 years or older with recurrent urinary retention referred for TURP entered this prospective, multicentre study. Several demographic, intra-and postoperative parameters were assessed. Preoperative geriatric assessment was performed by the 7-item Canadian Study of Health and Ageing (CSHA) frailty scale (1: very fit, 7: severely frail; completion takes less than a minute). The main outcome parameters were successful voiding rates at discharge and 3 months postoperatively. Results: A total of 54 patients were recruited; 42 (77.8%) patients had a CSHA index of 1-3 and were considered as "fit", the remaining 12 (22.2%) formed the "frail" group (CSHA index 4-7). Age was identical in both cohorts (79.5 ± 3.7 vs. 79.7 ± 3.3 years); differences were demonstrable for the American Society of Anesthesiologists (ASA) score (p = 0.001), the number of daily medications (> 4: 32 vs. 75%, p = 0.02), falls within the past 6 months (12 vs. 33%), and the necessity of home/nursing care (5 vs. 42%, p = 0.004). Intra-and perioperative complications, duration of postoperative catheterization, and length of hospitalization were identical in both cohorts. The success rate at discharge was 80.6% in fit and 75.0% in frail patients; the respective values at 3 months were 95.2 and 83.3%. Conclusions: A simple 1-min geriatric assessment tool can predict -to a certain extentthe outcome of desobstructive surgery in older patients with recurrent urinary retention. Fit patients achieve an excellent outcome while frail patients might benefit from a more indepth urodynamic/geriatric evaluation.

show abstract

Section: Discussionmentioning

confidence: 91%

Can a Simple Geriatric Assessment Predict the Outcome of TURP?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Inclusion and exclusion criteria for the Rezum thermal therapy are mentioned as follows in Table 4 [36,37]. In contrast with some of the other techniques mentioned above, patients with a median lobe obstruction can still qualify to receive this therapy.…”

Section: Water Vapor Therapy (Rezum Tm )mentioning

confidence: 99%

“…This procedure is quite safe with a minimal perioperative effects. The most important advantages are ease (day procedure with no general anesthesia needed) and no reports of sexual dysfunction [7,36,37]. Other advantages include significant improvements in Qmax, IPSS, QoL, and PVR and cost-effectiveness.…”

Section: Water Vapor Therapy (Rezum Tm )mentioning

confidence: 99%

“…Other advantages include significant improvements in Qmax, IPSS, QoL, and PVR and cost-effectiveness. The most significant disadvantages include limited long-term data and inability to ascertain incidental cases of prostate cancer [7,36,37]. TURP, in contrast, provides benefit by collecting tissue specimens which can detect prostate cancer.…”

Section: Water Vapor Therapy (Rezum Tm )mentioning

confidence: 99%

“… BPH: benign prostatic hyperplasia, IPSS: international prostate symptom score, PVR: postvoid residual, Qmax: maximum urinary flow rate, PSA: prostate specific antigen, UTI: urinary tract infection. Adopted from Westwood et al (Ther Adv Urol 2018;10:327–33) [ 37 ]. …”

Section: Figmentioning

confidence: 99%

See 2 more Smart Citations

An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy

Srinivasan

Wang

2020

World J Mens Health

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH), a common cause of lower urinary tract symptoms in the elderly male population, has conventionally treated by transurethral resection of the prostate (TURP). During recent years, newer minimally invasive therapies (MITs) have entered the playing field and challenged TURP with their convenience, lack of sexual side effects, and overall safety. The present paper provides an update on the more heavily studied and most recent MITs, analyzing their mechanism of action, tolerability, and efficacy in clinical practice. Particularly, robust clinical data have propelled UroLift and Rezuum to the forefront in the armamentarium of minimally invasive BPH treatment. Newer mechanical therapies such as the temporary implantable nitinol device, ClearRing, ZenFlow Spring, and Butterfly are appealing options as they forego cutting, ablation, heating, or removing prostatic tissue. It is obvious that there is wide variation in the degree of clinical readiness of each modality and only time and long-term, multicenter studies will decide which of these therapies are accepted by the patient and urologist.

show abstract

Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia

et al. 2021

View full text Add to dashboard Cite

Objective Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. We sought to determine whether Rezūm is effective in the treatment of catheter‐dependent urinary retention secondary to BPH. Methods A retrospective chart review was conducted on consecutive patients who presented for urinary retention and subsequently treated with Rezūm. We evaluated procedural details and examined variables pre‐ and post‐Rezūm (at 6 months) including International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS–QOL), maximum flow (Qmax), post void residual volume (PVR), prostate specific antigen, rate of retention, and use of alpha blockers and 5‐alpha reductase inhibitor (5ARI). Results Of the 49 patients included in this study, median age of was 73 years, median prostate volume was 73cc (Interquartile range [IQR]: 50, 103) and a median lobe was present in 80% of patients. All patients were in urinary retention before treatment with a median PVR of 900 ml (IQR: 566, 1146). Following Rezum, IPSS (17 pre‐Rezūm, 4 post‐Rezūm) and IPSS–QOL (4 pre‐Rezūm, 1 post‐Rezūm) both improved at 6 months (p < 0.01). Qmax increased from 3 to 6 ml/s (p = 0.03) and PVR decreased from 900 to 78 ml (p < 0.01). Only 17/38 patients taking alpha‐blockers and 7/15 patients on 5ARIs continued therapy at 6 months following Rezūm (p < 0.01). Of the 49 patients treated, 10 (20.4%) remained in catheter dependent urinary retention following the procedure, and 6 remained in retention at 6 months (12.2%) even after further surgical therapies for BPH (p < 0.01). Conclusion Rezūm is a safe and effective therapy for treating catheter dependent urinary retention in patients with BPH, including those with median lobes. As a minimally invasive therapy, it is a promising option in patient, particularly those who are not suitable for prolonged anesthesia.

show abstract

Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia

Cited by 70 publications

References 21 publications

Can a Simple Geriatric Assessment Predict the Outcome of TURP?

Can a Simple Geriatric Assessment Predict the Outcome of TURP?

An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy

Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia

Contact Info

Product

Resources

About